Warner Chilcott  today announced that the FDA has
approved LO LOESTRINT FE (norethindrone acetate and ethinyl estradiol tablets,
ethinyl estradiol tablets and ferrous fumarate tablets) for the prevention of
pregnancy. LO LOESTRIN FE is a novel oral contraceptive that offers women the
lowest dosage of estrogen (10 mcg) of any oral contraceptive currently available
in the U.S.
market.

“We are excited about the approval of LO LOESTRIN FE,
which complements our women’s healthcare franchise and expands the product offerings
in our branded oral contraceptive portfolio,” said Roger Boissonneault,
President and CEO of Warner Chilcott.

The company anticipates the commercial launch of LO LOESTRIN
FE in early 2011.